Barclays Reiterates an 'Overweight' on Teva Pharmaceutical (TEVA); Stock Lull Creates Opportunity
Tweet Send to a Friend
Barclays reiterates an 'Overweight' rating on Teva Pharmaceutical (Nasdaq: TEVA), price target $73.
Barclays analyst says, "After a rebound from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "After a rebound from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
